Clinical Trial Update: Spironolactone Against Anthracycline-induced Cardiomyopathy [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluating spironolactone for anthracycline-induced cardiomyopathy has completed. The study was sponsored by TC Erciyes University.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anthracycline-induced Cardiomyopathy

Drugs mentioned

• Spironolactone (spironolactone)

Snippet

Sponsor: TC Erciyes University | Conditions: Anthracycline Induced Cardiotoxicity | Phase 4 | Status: COMPLETED